MeiraGTx

MeiraGTx is a vertically integrated, clinical-stage genetic medicines company developing AAV-based gene therapies for inherited retinal diseases, neurodegenerative conditions, and salivary gland disorders.

The company operates end-to-end capabilities spanning viral vector design, GMP manufacturing, and clinical development, with a cGMP facility in London supporting IND-to-commercial supply.

A proprietary riboswitch gene regulation platform enables dose-responsive control of transgene expression via oral small molecules.